APA (7th ed.) Citation

Christopoulos, P., Bozorgmehr, F., Brückner, L. M., Chung, I., Krisam, J., Schneider, M., . . . Thomas, M. (2021). Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial. BMC cancer, 21, . https://doi.org/10.1186/s12885-021-08460-w

Chicago Style (17th ed.) Citation

Christopoulos, Petros, et al. "Brigatinib Versus Other Second-generation ALK Inhibitors as Initial Treatment of Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer with Deep Phenotyping: Study Protocol of the ABP Trial." BMC Cancer 21 (2021). https://doi.org/10.1186/s12885-021-08460-w.

MLA (9th ed.) Citation

Christopoulos, Petros, et al. "Brigatinib Versus Other Second-generation ALK Inhibitors as Initial Treatment of Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer with Deep Phenotyping: Study Protocol of the ABP Trial." BMC Cancer, vol. 21, 2021, https://doi.org/10.1186/s12885-021-08460-w.